Evaluation of immunoreactivity to erbB-2 protein as a marker of prognosis in bile duct carcinoma
Motojima, K.; Komuta, K.; Hiasa, A.; Tsuribune, T.; Hashimoto, T.; Tsunoda, T.; Kanematsu, T.
Nihon Geka Gakkai Zasshi 93(9): 952-955
1992
ISSN/ISBN: 0301-4894 PMID: 1361658 Document Number: 400327
Recent studies of erbB-2 expression have shown that the erbB-2 oncoprotein correlated with poor prognosis of patients with breast cancer. Surgical treatment of the bile duct carcinoma is currently unsatisfactory. To evaluate erbB-2 oncoprotein as a marker of prognosis, we analyzed 68 bile duct carcinomas immunohistologically, using monoclonal antibody against erbB-2 oncoprotein, as well as clinicopathological data and outcome. High incidence of expression of erbB-2 oncoprotein was shown in bile duct carcinoma. Positive rates of erbB-2 oncoprotein correlated with stage of bile duct carcinoma. Survival of patients with erbB-2 expression cancer was shorter than those without erbB-2 expression cancer and erbB-2 expression has a prognostic value in bile duct carcinoma.